The structure and substrate specificity of human Cdk12/Cyclin K
Open accessThe DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Phosphorylation of the RNA polymerase II C-terminal domain (CTD) by cyclin-dependent kinases is important for productive transcription. Here we determine the crystal structure of Cdk12/CycK and analyse its requirements for substrate recognition. Active Cdk12/CycK is arranged in an open conformation similar to that of Cdk9/CycT but different from those of cell cycle kinases. Cdk12 contains a C-terminal extension that folds onto the N- and C-terminal lobes thereby contacting the ATP ribose. The interaction is mediated by an HE motif followed by a polybasic cluster that is conserved in transcriptional CDKs. Cdk12/CycK showed the highest activity on a CTD substrate prephosphorylated at position Ser7, whereas the common Lys7 substitution was not recognized. Flavopiridol is most potent towards Cdk12 but was still 10-fold more potent towards Cdk9. T-loop phosphorylation of Cdk12 required coexpression with a Cdk-activating kinase. These results suggest the regulation of Pol II elongation by a relay of transcriptionally active CTD kinases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Cdk12 activity on the CTD requires Ser7 prephosphorylation. (a) Design of CTD substrate peptides used for kinetic and ESI-MS analyses. Peptides contained three consensus hepta-repeats with either no modification (cons. CTD[3]) or with phosphorylation marks continuously set at one residue of the heptad sequence as shown for Ser7 (pS7-CTD[3]). The same design principle was used for CTD peptides phosphorylated at Tyr1 (pY1-CTD[3]), Ser2 (pS2-CTD[3]), Thr4 (pT4-CTD[3]) and Ser5 (pS5-CTD[3]) or a peptide that contained a lysine at position 7 (K7-CTD[3]). (b) Activity of Cdk12/CycK for various CTD substrates. Of the seven peptides tested, Cdk12 showed the highest activity for continuous Ser7 prephosphorylation. Minor activities were detected for Ser2 and Thr4 prephosphorylated peptides. Remarkably, no activity was seen for cons. CTD[3] or the K7-peptide, which is in contrast to P-TEFb. In addition, Cdk12 exhibited no activity on the pSer5 peptide. (c) ESI-MS analyses of CTD peptides before and after 4 h of incubation with 2 μM Cdk12/CycK. Whereas no phosphorylation occurred for the consensus peptide, the pS7-CTD[3] substrate got readily phosphorylated up to three times. (d) Time course of Cdk12/CycK mediated CTD phosphorylation. The prephosphorylated Ser7 peptide got phosphorylated over time to saturation, while the non-phosphorylated peptide showed low susceptibility as a Cdk12 substrate. Data in panels b and d are the mean±s.d. of three independent experiments.](https://figures.cochat.ai/paper-figures/10d663b65180482a83bae3bf104eeec2/the-structure-and-substrate-specificity-of-human-cdk12-cyclin-k-figure-3.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CR8 is a pleiotropic CDK inhibitor reported to bind CDK1/2/3/5/7/9/126,19”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, we identified cyclin-dependent kinase 12 (CDK12), which is a known target of CR819 and whose activity depends on the interaction with cycK20, as a crucial component for CR8-induced cycKeGFP destabilisation (Fig. 1g, Extended Data Fig. 2h–k).”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CDK12 and CDK13 are two structurally similar kinases that has the ability to phosphorylate serine 2 of the POLII CTD heptad repeats (Bösken et al., 2014; Dixon-Clarke et al., 2015; Greifenberg et al., 2016).”
From Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation (2020) · cites this paper as Bösken et al., 2014
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The density for this region could only be tentatively assigned, likely due to the presence of multiple conformations, but the CDK12 C-terminal tail clearly engages with DDB1 and assumes a conformation different from those seen in isolated CDK12-cycK structures (Extended Data Fig. 6a, b, d)19,21.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,317
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
The Conformational Plasticity of Protein Kinases
Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,752
Transcriptional Regulation and Its Misregulation in Disease
Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.02.014 · Cited by 1,620
Diverse somatic mutation patterns and pathway alterations in human cancers
Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., Stern, H. M., Yue, P., Haverty, P. M., Bourgon, R., Zheng, J., et al. (2010) · Nature · doi:10.1038/nature09208 · Cited by 1,027
Cited by
Items 101–198 of 198
Ni, Z., Ahmed, N., Nabeel‐Shah, S., Guo, X., Pu, S., Song, J., Marcon, E., Burke, G. L., Tong, A. H. Y., Chan, K., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae240 · Cited by 31
“Instead, the two proteins are tightly bound in a complex ( 105 ) and are responsible for S2 phosphorylation of the RNAP II CTD ( 106 ), which is crucial for 3 (cid:2) end processing ( 21 ,107 ) and the interaction of certain CPA factors (e.g. PCF11) with the CTD ( 100 ).”
JUNB promotes the survival of Flavopiridol treated human breast cancer cells
Hicks, M. J., Hu, Q., Macrae, E. R., & DeWille, J. W. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.05.057 · Cited by 19
“The kinase responsible for the phosphorylation events that result in the delayed induction of JUNB gene expression has not been identified but could include kinases capable of phosphorylating the Pol II CTD on serine 2, including Brd4 or CDK12 [6,32,33].”
BackgroundChai, Q., Li, S., Collins, M. K., Li, R., Ahmad, I., Johnson, S. F., Frabutt, D. A., Yang, Z., Shen, X., Sun, L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109514 · Cited by 21
“, 2011), phosphorylates the C-terminal domain of RNA polymerase II (Bösken et al., 2014; Greifenberg et al., 2016) and consequently regulates genome stability and RNA processing.”
BackgroundAng, H. X., Sutiman, N., Deng, X., Liu, A., Cerda-Smith, C. G., Hutchinson, H. M., Kim, H., Bartelt, L. C., Chen, Q., Barrera, A., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221448120 · Cited by 21
Huang, C., Xu, Q., Dai, C., Wang, L., Tien, Y.-C., Li, F., Su, Q., Huang, X., Wu, J., Zhao, W., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c04570 · Cited by 18
Phosphorylation of RNA Polymerase II by CDKC;2 Maintains the Arabidopsis Circadian Clock Period
Uehara, T., Nonoyama, T., Taki, K., Kuwata, K., Sato, A., Fujimoto, K. J., Hirota, T., Matsuo, H., Maeda, A. E., Ono, A., et al. (2022) · Plant and Cell Physiology · doi:10.1093/pcp/pcac011 · Cited by 18
Ser7 of RNAPII-CTD facilitates heterochromatin formation by linking ncRNA to RNAi
Kajitani, T., Kato, H., Chikashige, Y., Tsutsumi, C., Hiraoka, Y., Kimurâ, H., Ohkawa, Y., Obuse, C., Hermand, D., & Murakami, Y. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714579115 · Cited by 18
“Bösken CA, et al. (2014) The structure and substrate specificity of human Cdk12/Cyclin K. Nat Commun 5:3505.”
Coming of Age: Targeting Cyclin K in Cancers
Xiao, Y., & Dong, J. (2023) · Cells · doi:10.3390/cells12162044 · Cited by 20
“The Cyclin K-CDK12 and Cyclin K-CDK13 complexes preferentially phosphorylate the Ser2 and Ser5 of the CTD and, to a much lesser extent, Ser7 in vitro [37,41,42].”
Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity
Huang, Y., Liu, W., Zhao, C., Shi, X., Zhao, Q., Jia, J., & Wang, A. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116547 · Cited by 19
CDK12 Activity-Dependent Phosphorylation Events in Human Cells
Bartkowiak, B., Yan, C. M., Soderblom, E. J., & Greenleaf, A. L. (2019) · Biomolecules · doi:10.3390/biom9100634 · Cited by 18
CDK12 Promotes Cervical Cancer Progression through Enhancing Macrophage Infiltration
Yang, B., Chen, J., & Teng, Y. (2021) · Journal of Immunology Research · doi:10.1155/2021/6645885 · Cited by 17
“In vitro, CDK12 also potentially modulates transcription initiation by phosphorylation of RNA Pol II at Ser5 and takes part in a series of cellular biological processes including DNA damage response (DDR), the proliferation of the cell, splicing of precursor mRNA, and the process of pretranscriptional mRNA [8, 9].”
RNAPII driven post-translational modifications of nucleosomal histones
Chan, W. S., Kumar, A., & Kono, H. (2022) · Trends in Genetics · doi:10.1016/j.tig.2022.04.010 · Cited by 16
Transcription-associated cyclin-dependent kinase 12 (CDK12) as a potential target for cancer therapy
Wu, W., Yu, S., & Yu, X. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188842 · Cited by 16
Troester, S., Eder, T., Wukowits, N., Piontek, M., Fernández‐Pernas, P., Schmoellerl, J., Haladik, B., Manhart, G., Allram, M., Maurer‐Granofszky, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59930-9 · Cited by 14
“The CDK12 kinase-dead variant CDK12 D873N was designed as the murine equivalent of the previously published human CDK12 D877N kinase-dead mutant 57 .”
Yeh, S., Lin, C., Li, C., & Chen, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102536 · Cited by 15
“When it phosphorylates to increase its own kinase activity to regulate transcription factors [36], its mutation activates TF NFE2L1, leading to the expression of downstream oncogenes.”
BackgroundStructural Motifs for CTD Kinase Specificity on RNA Polymerase II during Eukaryotic Transcription
Ramani, M. K. V., Escobar, E. E., Irani, S., Mayfield, J. E., Moreno, R. Y., Butalewicz, J. P., Cotham, V. C., Wu, H., Tadros, M. M., Brodbelt, J. S., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00474 · Cited by 15
Structure and activation mechanism of the yeast RNA Pol II CTD kinase CTDK-1 complex
Xie, Y., Lord, C. L., Clarke, B. P., Ivey, A. L., Hill, P. S., McDonald, W. H., Wente, S. R., & Ren, Y. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019163118 · Cited by 14
Control of non-productive RNA polymerase II transcription via its early termination in metazoans
Rouvière, J. O., Lykke‐Andersen, S., & Jensen, T. H. (2022) · Biochemical Society Transactions · doi:10.1042/bst20201140 · Cited by 14
Kopczyńska, M., Saha, U., Romanenko, A., Nojima, T., Gdula, M. R., & Kamieniarz-Gdula, K. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae1240 · Cited by 16
Ghosh, P., Schmitz, M., Pandurangan, T., Tadesse, S., Chan, S. C., Mosior, J., Sun, L., Palve, V. C., Grassie, D., Anand, K., et al. (2024) · RSC Chemical Biology · doi:10.1039/d4cb00190g · Cited by 17
Self-citationTFIIH kinase CDK7 drives cell proliferation through a common core transcription factor network
Jones, T., Feng, J., Luyties, O., Cozzolino, K., Sanford, L., Rimel, J. K., Ebmeier, C. C., Shelby, G. S., Watts, L. P., Rodino, J., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr9660 · Cited by 15
“Unlike SY-5609, flavopiridol is a pan-kinase inhibitor that blocks multiple transcription-associated CDKs, including CDK9, CDK12, and CDK13 ( 34 – 36 ).”
Research progress of anticancer drugs targeting CDK12
Yan, Z., Du, Y., Zhang, H., Zheng, Y., Lv, H., Dong, N., & He, F. (2023) · RSC Medicinal Chemistry · doi:10.1039/d3md00004d · Cited by 12
Hao, Q., Zhao, W., Li, Z., Lai, Y., Wang, Y., Yang, Q., & Zhang, L. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117465 · Cited by 14
Bai, Y., Liu, Z., Li, Y., Zhao, H., Lai, C., Zhao, S., Chen, K., Luo, C., Yang, X., & Wang, F. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c01697 · Cited by 13
CDK regulation of transcription by RNAP II: Not over ‘til it's over?
Fisher, R. P. (2016) · Transcription · doi:10.1080/21541264.2016.1268244 · Cited by 18
Self-citationUnveiling the noncanonical activation mechanism of CDKs: insights from recent structural studies
Li, T., Tang, H.-C., & Tsai, K. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1290631 · Cited by 13
Sun, R., Peng, J. C., Wang, Z., Yan, B., Zhu, S., Huang, Z., Zhang, J., Ding, D., Li, X., Wang, L., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413732122 · Cited by 11
A patent and literature review of CDK12 inhibitors
Tang, R., Liu, J., Li, S., Zhang, J., Yu, C., Liu, H., Chen, F., Lv, L., Zhang, Q., Yuan, K., et al. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2126765 · Cited by 12
Disrupting the Molecular Pathway in Myotonic Dystrophy
Xing, X., Kumari, A., Brown, J., & Brook, J. D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413225 · Cited by 12
Discovery of small molecule degraders for modulating cell cycle
Wang, L., Yang, Z., Li, G., Liu, Y., Ai, C., & Rao, Y. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1027-5 · Cited by 10
Pitolli, C., Marini, A., Sette, C., & Pagliarini, V. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01413-3 · Cited by 12
Dai, W., Xie, D., Huang, H., Li, J., Guo, C., Cao, F., Yang, L., Zhong, C., & Liu, S. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101173 · Cited by 12
Alrouji, M., Alshammari, M. S., Anwar, S., Venkatesan, K., & Shamsi, A. (2025) · Cancers · doi:10.3390/cancers17091554 · Cited by 12
Zheng, S., Chen, Y., Zhu, Z., Li, N., He, C., Koeffler, H. P., Han, X., Wei, Q., & Xu, L. (2025) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b2500021 · Cited by 11
“The single in ‐ hibition of either CDK12 or CDK13 elicits transcrip ‐ tional programs associated with the DNA damage re ‐ sponse (DDR) and genome stability (Bösken et al., 2014; Tien et al., 2017), but has limited impacts on cell viability.”
Drugging the undruggable: Chemical and biological insights into molecular glues in the pipeline
Metwally, K. A., Yahya, G., & Abo-Dya, N. E. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118132 · Cited by 10
Luyties, O., Sanford, L., Rodino, J., Nagel, M., Jones, T., Rimel, J. K., Ebmeier, C. C., Palacio, M., Shelby, G. S., Cozzolino, K., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115904 · Cited by 11
Ma, B., Ma, C., Li, J., & Fang, Y. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1006964 · Cited by 8
“For example, the hyper-phosphorylated CDK kinases, CDK2, CDK1, and CDK12 in worker embryos suggest that kinase activity is induced to catalyze the target proteins, thus driving the cell cycle to cement the needs of organogenesis (Supplementary Table S14).”
BackgroundInfluentialHerpes simplex virus 1 inhibits phosphorylation of RNA polymerase II CTD serine-7
Whisnant, A. W., Dionisi, O. D., Sanchez, V. S., Rappold, J. M., Djaković, L., Grothey, A., Marante, A. L., Fischer, P., Peng, S., Wolf, K., et al. (2024) · Journal of Virology · doi:10.1128/jvi.01178-24 · Cited by 8
“The reduction of pS7 could also result in more subtle, global consequences on host gene expression as pS7 has been proposed to suppress cryptic transcription (66) as well as stimulate Ser2 phosphorylation by CDK9 and CDK12 (67, 68).”
Kuzmina, A., Verstraete, N., Galker, S., Maatook, M., Bensaude, O., & Taube, R. (2014) · Retrovirology · doi:10.1186/1742-4690-11-51 · Cited by 11
“The MRAIL motif - YRQQ40A in the N-terminus cyclin box repeat of CycT1 (which on Cdk2 is located on helix H1 and is known to be part of the recognition motif of the cyclin to its substrate or inhibitors), also constitutes part of the Tat binding surface of CycT1 [37,38].”
Shimizu, K., Sano, T., Mizuno, K., Sunada, T., Makita, N., Hagimoto, H., Goto, T., Sawada, A., Fujimoto, M., Ichioka, K., et al. (2022) · Molecular Case Studies · doi:10.1101/mcs.a006194 · Cited by 8
Gajdušková, P., Mozos, I. R. D. L., Hluchý, M., Myšková, A., Zábrady, K., Maník, P., Dragišić, N., Hanáková, K., Potěšil, D., Bologna, S., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-71119-2 · Cited by 9
The point of no return: The poly(A)-associated elongation checkpoint
Tellier, M., Vicens, I. F., & Murphy, S. (2016) · RNA Biology · doi:10.1080/15476286.2016.1142037 · Cited by 9
Gupta, P. P., Bastikar, V. A., Kučiauskas, D., Kothari, S. L., Cicenas, J., & Valius, M. (2017) · Medical Oncology · doi:10.1007/s12032-017-1011-5 · Cited by 7
“Cyclin-dependent kinases are important for productive transcription [47].”
BackgroundHigh-resolution cryo-EM of a small protein complex: The structure of the human CDK-activating kinase
Greber, B. J. (2024) · Structure · doi:10.1016/j.str.2024.03.003 · Cited by 7
Ferguson, F. M., Doctor, Z. M., Ficarro, S. B., Marto, J. A., Kim, N. D., Sim, T., & Gray, N. S. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.05.024 · Cited by 7
Substrate Specificity of the Kinase P-TEFb towards the RNA Polymerase II C-Terminal Domain
Gibbs, E. B., Laremore, T. N., Usher, E. T., Portz, B., Cook, E. C., & Showalter, S. A. (2017) · Biophysical Journal · doi:10.1016/j.bpj.2017.09.011 · Cited by 5
Tyro3 Targeting as a Radiosensitizing Strategy in Bladder Cancer through Cell Cycle Dysregulation
Silina, L., Dufour, F., Rapinat, A., Réyès, C., Gentien, D., Maksut, F., Radvanyi, F., Verrelle, P., Bernard‐Pierrot, I., & Mégnin-Chanet, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158671 · Cited by 5
Structural basis of Cdk7 activation by dual T-loop phosphorylationPreprint
Düster, R., Anand, K., Binder, S. C., Schmitz, M., Gatterdam, K., Fisher, R. P., & Geyer, M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.14.580246 · Cited by 5
Self-citationCao, Y., Huang, S., He, Y., Zhang, Y., Chen, S., Huang, M., He, F., Chen, S., Wang, L., Yang, Z., et al. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108302 · Cited by 4
Robert, T., Dock‐Brégeon, A., & Colas, P. (2021) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1782 · Cited by 5
CDK12 loss inhibits cell proliferation by regulating TBK1 in non-small cell lung cancer cells
Liu, X., Liu, Y., Chai, W.-J., Yan, M., Li, H., Li, J., Sun, L., Cao, Y. Z., Liu, Q., Sun, Y., et al. (2023) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2023.101923 · Cited by 4
Actin associates with actively elongating genes and binds directly to the Cdk9 subunit of P-TEFb
Kyheröinen, S., Prajapati, B., Sokolova, M., Schmitz, M., Viita, T., Geyer, M., & Vartiainen, M. K. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.105698 · Cited by 4
“Of note, Cdk12/Cyclin K and Cdk9/Cyclin T1 share structural similarity, having open conformations (59), whereas Cdk7/ Cyclin H form is more closed (60).”
BackgroundSelf-citationCyclin-dependent kinases as mediators of aberrant transcription in prostate cancer
Rahman, R., & Selth, L. A. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102378 · Cited by 5
“CDK12 [54] and CDK13 [55] both form a complex with cyclin K and can also phosphorylate the RNA pol II CTD at Ser2 (Fig.”
Sudarshan, N., Asalam, M., Kumar, A., Singh, N., Gupta, A., De, I., Singh, S. K., Zhang, K. Y. J., & Akhtar, M. S. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110365 · Cited by 3
“The role of Ser7 phosphorylation (Ser7P) is attributed to priming the function of other kinases, which in turn is helpful in the recruitment of RPAP2 phosphatase and the integrator complex for some small nuclear RNA (snRNAs; U1 and U2 snRNA) transcription in humans (16 – 18).”
Roles of CDK12/CDK13 and development of inhibitors and degraders
Li, Z. F., Ke, Y., Zhang, R., Zhang, R., & Zhang, L. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119077 · Cited by 4
The MYCN/Aurora-A complex is a cyclin activating kinase for CDK12Preprint
Müller, M., Eing, L., Uhl, L., Schmitz, M., Kaneva, I. N., Byrne, D. P., Fleischhauer, D., Burgess, S. G., Fischer, S., Gebauer, N., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.15.633177 · Cited by 4
Self-citationAbsence of CDK12 in oocyte leads to female infertility
Jansová, D., Sedmikova, V., Berro, F. J., Aleshkina, D., Dvoran, M., Kubelka, M., Rezacova, J., Rutarova, J., Kohoutek, J., & Šušor, A. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07536-w · Cited by 2
CDK12-Mediated Phosphorylation of FOXA1 Promotes Prostate Cancer Progression via the MDM2–p53 Axis
Yan, B., Huang, M., Wang, J., Lei, H., Tong, T., Xu, B., Cao, F., Teng, Q., Huang, J., Guan, Y., et al. (2025) · Research · doi:10.34133/research.0990 · Cited by 5
“In a manner similar to the D877N mutation [ 28 ], which is recognized as a kinase-dead mutant of CDK12, the expression of these PCa-associated mutants consistently resulted in the loss of CDK12’s ability to phosphorylate FOXA1 (Fig.”
Liu, Y., Yang, Z., Liao, Z., Chen, S., Qin, Z., Liang, Z., Chen, L., Bao, C., Wei, M., Zhang, L., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01681 · Cited by 2
Pandurangan, T., Zeleke, S. T., Iermolaieva, A., Ghosh, P., Mosior, J., Sun, L., Grassie, D., Schmitz, M., Kalaga, M. N., Albritton, W., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02086 · Cited by 4
Self-citationEmerging pharmacology of targeted protein degraders
Barghout, S. H., & Eldeeb, M. A. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103694 · Cited by 2
Development of CDK12 as a Cancer Therapeutic Target and Related Inhibitors
Chen, B., & Liu, J. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096307629240611104728 · Cited by 2
Relay of cyclin-dependent kinases in the regulation of axonal growth.
Chang, T.-Y., & Cheng, P.-L. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.06.019 · Cited by 2
Therapeutic targeting of CDK12: a medicinal chemistry perspective
Wang, F., Dai, H., Wan, K., & Wang, M. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118552 · Cited by 1
Protein Complex Production from the Drug Discovery Standpoint
Moarefi, I. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-27216-0_1 · Cited by 1
Structure-independent machine-learning predictions of the CDK12 interactome
Karolak, A. M., Urbaniak, K., Monastyrskyi, A., Duckett, D. R., Branciamore, S., & Stewart, P. A. (2024) · Biophysical Journal · doi:10.1016/j.bpj.2024.05.017 · Cited by 1
FragLite mapping to identify the BRD4 recruitment site of P-TEFbPreprint
Hope, I., Heath, R., Baslé, A., Martin, M. P., Waring, M. J., Endicott, J., Noble, M. E. M., & Tatum, N. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.09.717428 · Cited by 1
“This arrangement creates a prominent cleft between the C-terminal lobes that is either not present (for example in CDK2-cyclin A [49] or less prominent (for example in CDK4-cyclin D [50] [51]) or CDK12-cyclin K [52] in other CDK-cyclin pairs.”
dos Santos, N. P. F. (2015) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.75.2015.tde-16062015-091524 · Cited by 4
Regulation of alternative polyadenylation in Drosophila melanogaster
Oliveira, M. (2019) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/zrjc-r941
Liu, X. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7710
Chemical Baiting Fishes Out CDKC;2 as a Novel Arabidopsis Clock Modulator
Noutoshi, Y. (2022) · Plant and Cell Physiology · doi:10.1093/pcp/pcac026
Dawson, M. A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738066001.793575550
Mohammad, E. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9383
Tumor suppression by RNA surveillance
Fisher, R. P. (2023) · Science · doi:10.1126/science.adh4051
Self-citationThe spreading of facultative H3K9me3-heterochromatin drives congenital diseasePreprint
Wang, C., Zhang, W., Chen, X., Wang, W., Li, Y.-H., Chang, J.-F., Guo, X.-B., Jing, Y., Li, Y., Lu, X., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.11.552907
Zehra, Alnajjar, L. I., Alshammari, N. I., Ishrat, R., & Hassan, M. I. (2025) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2025.0060
“CDK12 is activated when bound to its regulatory partner, Cyclin K, which alters the protein ’ s con fi guration to achieve the active state (Bösken et al., 2014).”
Murugavelu, P., Glebko, H., Rani, J., Tickotsky, N., Levin, L., Kuzmina, A., & Taube, R. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.10.705011
Exploitation du défaut de réparation de l'ADN à l'aide de la stratégie d'inhibition de CDK
Orhan, E. (2022) · theses.fr (ABES) · doi:10.70675/40065dd4z1f5bz4361zaa67z59acc4e5d6c2
Tran, H., Gomes, I., Chaudhuri, A., Nazari, A., Ahmadi, S., Végh, H., Carneiro, A. N. B. M., Höglund, U., Krintel, C., Svanborg, C., et al. (2026) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiag243
“As the RK48 sequence is positioned at the cyclin K binding site of CDK12 [27] the interaction was predicted to inhibit the kinase activity of CDK12 and subsequent RPB1 phosphorylation (Figure 2 F and Supplementary Figure 6).”
CDK12 and CDK13 suppress distinct intronic polyadenylation sitesPreprint
Hulver, M. J., Polevoda, A., Huang, K.-L., Wagner, E. J., & Boutz, P. L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.15.725461
Watlington, W. K., Dayanidhi, D. L., Zokaasadi, M., Mantyh, J. B., Olawuni, P., Rupprecht, G., Force, J. M., McCall, S. J., Bahl, A. K., Hsu, D. S., et al. (2026) · Molecular Oncology · doi:10.1002/1878-0261.70290
Mechanisms of transcription termination across the coding and noncoding loci of the genome
Song, A., Hu, M., & Chen, F. (2026) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-026-01005-8 · Cited by 1
Zheng, S., Shen, Z., Wu, Y., Huang, X., Zhang, Z., Liu, J., Wei, Q., Chen, W., Chen, Y., & Xu, L. (2026) · MedComm · doi:10.1002/mco2.70898
“These differences may underlie their mechanistic distinctions in functional complex assembly and substrate engagement [ 25 ].”
Targeting CDKs in the RNAPII transcription cycle
Fisher, R. P., & Geyer, M. (2026) · Nature Reviews Drug Discovery · doi:10.1038/s41573-026-01517-0 · Cited by 1
“3a,c) and was first resolved in the crystal structures of CDK12/cyclin K and CDK13/cyclin K 197,198 .”
Self-citationPrediction of pH-sensing histidine residues in human cellsPreprint
Sallah, S. R., & Warwicker, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.09.14.751505
A guide to transcriptional cyclin‐dependent kinases in cancer
Devlin, J. R., Kyheröinen, S., & Johnstone, R. W. (2026) · FEBS Journal · doi:10.1111/febs.70731
Murugavelu, P., Rani, J., Glebko, H., Ambiel, I., Tibroni, N., Tickotsky, N., Heyn, F., Schommers, P., Levin, L., Kuzmina, A., et al. (2026) · EMBO Molecular Medicine · doi:10.1038/s44321-026-00536-z
BindingDB (2025) · UC San Diego · doi:10.7270/q2vh5th3
BindingDB Entry 50047845: Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy.
BindingDB (2018) · UC San Diego · doi:10.7270/q2g73gp8
BindingDB (2023) · UC San Diego · doi:10.7270/q28k7f2w
BindingDB Entry 50020014: Research progress of anticancer drugs targeting CDK12.
BindingDB (2024) · UC San Diego · doi:10.7270/q25d8x7n
Novel Therapeutic Strategies in Lung Cancer
Kurtyka, C. A. (2014) · Digital Commons - University of South Florida (University of South Florida)
Metadata
- Authors
- Bösken, C. A., Farnung, L., Hintermair, C., Merzel Schachter, M., Vogel-Bachmayr, K., Blazek, D., Anand, K., Fisher, R. P., Eick, D., & Geyer, M.
- Affiliations
- Center of Advanced European Studies and Research (DE)
- Max Planck Institute of Molecular Physiology (DE)
- Center for Integrated Protein Science Munich (DE)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Geyer, Matthias
- Venue
- Nature Communications
- Published
- 2014-03-24
- Volume
- 5
- Issue
- 1
- Pages
- 3505-3505
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3973122
- OpenAlex
- W2074045994
- Semantic Scholar
- 7f2f1f4958b1ced0a261be63f6b87c33e72321b5
- Cited by
- 191
- References
- 60
- Citations by year
- 2026: 15 · 2025: 21 · 2024: 16 · 2023: 13 · 2022: 18 · 2021: 19 · 2020: 21 · 2019: 12 · 2018: 7 · 2017: 14 · 2016: 13 · 2015: 13 · 2014: 9
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Nature Communications (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- Max Planck Digital Library (submittedVersion)
- Max Planck Digital Library (submittedVersion, other-oa)
- Site cant be reached (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft (SFB 684, SFB/TR 5)
- Grantová Agentura České Republiky (CZ.1.05/1.1.00/02.0068, GA14-09979S)
- Central European Institute of Technology (CZ.1.05/1.1.00/02.0068., CZ.1.05/1.1.00/02)
- International Max Planck Research School for Advanced Methods in Process and Systems Engineering
- National Institutes of Health
- National Cancer Institute (T32-CA78207, T32CA078207)
- National Institute of General Medical Sciences (GM104291, R01GM104291)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- CDK12, cyclin K, cyclin-dependent kinases, RNA polymerase II C-terminal domain, CTD phosphorylation, substrate specificity, crystal structure, flavopiridol, T-loop phosphorylation, CDK-activating kinase, transcription elongation
- MeSH terms
- Crystallization, Enzyme-Linked Immunosorbent Assay, HeLa Cells, Humans, Models, Molecular, Protein Conformation, Mass Spectrometry, Substrate Specificity, Blotting, Western, Cyclins, Cyclin-Dependent Kinases, Multiprotein Complexes, Immunoprecipitation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.